4.6 Article

Pilot Study: Elevated Circulating Levels of the Proinflammatory Cytokine Macrophage Migration Inhibitory Factor in Patients With Chronic Spinal Cord Injury

Journal

ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION
Volume 94, Issue 8, Pages 1498-1507

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.apmr.2013.04.004

Keywords

Cytokines; Inflammation; Macrophage migration-inhibitory factors; Rehabilitation; Spinal cord injuries

Funding

  1. Feinstein Institute for Medical Research
  2. Feinstein Institute for Medical Research North Shore-Long Island Jewish Health System General Clinical Research Center
  3. National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [M01 RR018535]

Ask authors/readers for more resources

Objective: To test the hypothesis that the proinflammatory cytokine macrophage migration inhibitory factor (MIF) is elevated in the circulation of patients with chronic spinal cord injury (SCI) relative to uninjured subjects, and secondarily to identify additional immune mediators that are elevated in subjects with chronic SCI. Design: Prospective, observational pilot study. Setting: Outpatient clinic of a department of physical medicine and rehabilitation and research institute in an academic medical center. Participants: Individuals with chronic (>1y from initial injury) SCI (n = 22) and age- and sex-matched uninjured subjects (n = 19). Interventions: Not applicable. Main Outcome Measures: Plasma levels of MIF, as determined by a commercially available multiplex suspension immunoassay. The relationship between MIF levels and clinical/demographic variables was also examined. As a secondary outcome, we evaluated other cytokines, chemokines, and growth factors. Results: Plasma MIF levels were significantly higher in subjects with chronic SCI than in control subjects (P<.001). Elevated MIF levels were not correlated significantly with any one clinical or demographic characteristic. Subjects with SCI also exhibited significantly higher plasma levels of monokine induced by interferon-gamma/chemokine C-X-C motif ligand 9 (P<.03), macrophage colony stimulating factor (P<.035), interleukin-3 (P<.044), and stem cell growth factor beta (SCGF-beta) (P<.016). Among subjects with SCI, the levels of SCGF-beta increased with the time from initial injury. Conclusions: These data confirm the hypothesis that MIF is elevated in subjects with chronic SCI and identify additional novel immune mediators that are also elevated in these subjects. This study suggests the importance of examining the potential functional roles of MIF and other immune factors in subjects with chronic SCI. (c) 2013 by the American Congress of Rehabilitation Medicine

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available